Follow Up In Chest Tumors: Value Of Integrated PET/CT | 33079
OMICS Journal of Radiology
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Objective: To identify the value of PET-CT in follow up of chest tumors.
Patients & Methods: Whole body PET/CT studies were performed on 29 patients of variable primary & secondary chest tumors.
Results: Our findings indicate that FDG PET/CT has an important impact on follow up of chest tumors, as it delineated the metabolic
activity of the disease in 21 patients (72.41%), outlined the metabolic activity of the tumoral residue in 4 patients postoperatively
(13.79%), delineated the metabolic activity of the disease for preparing for BMT in 2 patients (6.89%), differentiated between tumoral
residue & post irradiation pneumonitis in 1 patient (3.44%), and in 1 patient initial assessment of the metabolic activity of the disease
before determination line of treatment.
Conclusion: Integrated PET/CT imaging, which combines both functional and morphologic imaging in a single examination, has
shown how the initial staging and subsequent follow-up of patients with chest tumors can supersede the traditional methods of
evaluation in terms of diagnostic accuracy and has an impact on the management. Limitations which must be kept in mind are the
subcentimetric pulmonary nodules that below 7 or 8 mm (beyond PET resolution) which can be overcome by short follow up.
Heba Nabil, is a MD candidate, he got his Master degree of radio-diagnosis at Faculty of Medicine, Ain Shams University in 2008. He did his first part of MD in 2012 and first part of FRCR in 2013. He has published two papers named: Follow up in chest tumors: Value of integrated PET/CT and Role of PET/CT in management of chest tumors. He is working as a Radiology Specialist at Nasser Institute for research and treatment, Cairo, Egypt.